Molecular imaging — using radioactive tracers to visualize physiological processes rather than anatomy — is experiencing a commercial renaissance driven by the emergence of theranostics: using the same targeting molecule for both diagnosis and therapy. Lutetium-177 DOTATATE for neuroendocrine tumors and Lutetium-177 PSMA for prostate cancer have validated the theranostic commercial model and are driving unprecedented growth in nuclear medicine infrastructure investment. GE HealthCare's pharmaceutical diagnostics segment — $2.9 billion in 2025, growing at 15.6% — is the fastest-growing business in the company.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• PET
• CT Market Dynamics
• Long Axial Field of View PET
• CT
• SPECT
• CT Technology
• Theranostics Commercial Landscape
• Radiopharmaceutical Supply Chain
• GE HealthCare, Siemens, Philips Nuclear Medicine Strategy
• Emerging Tracers
Table of Contents
1. Executive Summary
2. Market Overview
3. PET
4. CT Market Dynamics
5. Long Axial Field of View PET
6. CT
7. SPECT
8. CT Technology
9. Theranostics Commercial Landscape
10. Radiopharmaceutical Supply Chain
11. GE HealthCare, Siemens, Philips Nuclear Medicine Strategy
12. Emerging Tracers
13. Competitive Landscape
14. Regional Market Analysis
15. Strategic Conclusions and Recommendations
16. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Regional Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Bayer
Cardinal Health
GE HealthCare
Lantheus
Novartis AAA
POINT Biopharma
Siemens Healthineers
